Surface Oncology, Inc.
NASDAQ: SURF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lisa McGrath
- Employees
- 35
- Headquarters
- Cambridge, United States
- IPO year
- 2018
- Market cap
- $65.1M
- Website
- https://www.surfaceoncology.com
Loading SURF…
Loading profile data…Frequently asked questions about SURF
What does Surface Oncology, Inc. (SURF) do?
Surface Oncology, Inc. is a clinical-stage biotechnology firm focused on discovering and developing innovative immuno-oncology treatments for cancer patients in the United States. Its pipeline features a range of antibody-based therapeutics, including NZV930, a fully human IgG4 monoclonal antibody designed to modulate extracellular adenosine pro...
Where does SURF trade?
Surface Oncology, Inc. (SURF) trades on the NASDAQ Global Market.
What sector is SURF in?
Surface Oncology, Inc. (SURF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Surface Oncology, Inc.?
Lisa McGrath is the chief executive officer of Surface Oncology, Inc. (SURF).
Where is Surface Oncology, Inc. headquartered?
Surface Oncology, Inc. is headquartered in United States.
Does SURF pay a dividend?
Surface Oncology, Inc. (SURF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SURF go public?
Surface Oncology, Inc. (SURF) completed its initial public offering in 2018.